Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2020

View Archived Issues

Liver-derived protein helps lung, kidney repair

Acepodia studies ACE-1702 in phase I trial in advanced or metastatic HER2-expressing solid tumors

Microbiome-produced metabolites improve gut health

Targovax presents 12-month efficacy and immunological data for ONCOS-102 in mesothelioma

VP-01 demonstrates significant benefit in preclinical model of severe pulmonary hypertension

Positive safety data reported for AR-501 in healthy subjects

Shenzhen Targetrx Biotechnology patents Ret inhibitors

New phase I/IIa study investigates rigosertib plus nivolumab for lung adenocarcinoma

Shanghai Institute of Materia Medica presents TNF-alpha antagonists

Jiangsu Chia Tai Tianqing Pharmaceutical Group discloses HBV antivirals

Betta Pharmaceuticals synthesizes new TRK inhibitors

Promising interim safety and immunogenicity phase II data presented for HB-101 vaccine

Interim trial data show antitumor activity with loncastuximab plus ibrutinib in DLBCL/MCL

HZDR divulges new TMEM97 ligands for PET imaging

Crescendo Biologics targets dysfunctional tumoral T cells with dual checkpoint inhibitor CB-213

First patient dosed in phase Ib study of nirogacestat plus belantamab mafodotin in multiple myeloma

Merck & Co. presents data from two phase III studies of V-114

LB-54640, the first oral MC4 receptor agonist for the treatment of rare genetic obesity

First-in-human study of in vivo imaging with Cu-64 SPION

miRagen reports preclinical observations with next-generation miR-29 mimic MRG-229 for IPF

FDA grants accelerated approval to Xpovio for relapsed or refractory DLBCL

Researchers find FOXD2 to be involved in syndromic CAKUT

AACR II: Innate immunity has good CAR-Ma for antitumor approaches

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...